DNAtrix, Inc. Licenses Myxoma Virus For New Immunotherapy Platform
HOUSTON, Nov. 8, 2016 /PRNewswire/ -- DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced it has entered into an exclusive license agreement with the University of Florida, Gainesville to develop a novel oncolytic virus platform. The platform is based on myxoma virus, a poxvirus that has been shown to have beneficial features for treating cancers.
A major advantage of the myxoma virus is its ability to attach to T lymphocytes and other white blood cells, which are then delivered to the patient to trigger tumor cell killing and antitumor immunity. Myxoma virus can be armed with multiple immune stimulatory genes, a feature shared by other large DNA viruses such as herpes simplex and adenovirus.
"The myxoma virus has unique properties for attacking cancer," said CEO Frank Tufaro, Ph.D. "We think this technology platform provides a new modality for delivery of a potent oncolytic virus to tumors by co-administering it along with T cells. We look forward to testing this 'Trojan horse' strategy in the clinic."
"The myxoma virus is a novel oncolytic candidate that does not infect normal human cells but has a unique ability to identify the damaged signaling pathways found in the majority of human cancers; thus, resulting in productive infections in the patient's cancer cells," stated Grant McFadden, Ph.D., Professor in the Department of Molecular Genetics & Microbiology at the University of Florida, College of Medicine.
DNAtrix is a privately held, clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix's lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, a brain cancer for which there is neither a cure nor adequate treatment. The company is backed by Morningside Ventures and Mercury Fund, and has been awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit the company website at www.DNAtrix.com.
Imran Alibhai, Ph.D.
S.V.P. Business Development
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dnatrix-licenses-myxoma-virus-for-new-immunotherapy-platform-300359303.html